The New England Journal of Medicine detailed findings of a sickle cell anemia treatment that showed promising data, marking huge strides in CRISPR technology as well as gene editing. These findings were published on December 5, 2020 and were also accompanied by a multitude of new findings from the American Society of Hematology (ASH) Annual Meeting & Exposition including Kite Pharma’s 4-year follow up data from their B-Cell Lymphoma drug.

Learn more here. 

More on: